Kohl probes device DTC, threatens ad ban push

Share this article:
Kohl probes device DTC, threatens ad ban push
Kohl probes device DTC, threatens ad ban push
Sen. Herb Kohl said he was “prepared to call for future moratoriums” on DTC for new medical devices, citing “real risks and serious complications.”

Kohl (D-WI), who chairs the Senate Special Committee on Aging, said “Physicians and consumers must be appropriately educated about these critical devices and their benefits and risks alike, What we do in the near term will be dependent on the proactive actions of FDA and industry.”

His comments followed committee hearings into DTC for medical devices in which physicians argued that device DTC undermines the doctor-patient relationship and can raise healthcare costs. Upbeat ads for the Cypher stent, from J&J's Cordis, came in for special criticism. Cordis' “Life wide open” TV campaign debuted last Thanksgiving but has since been restricted to a single market outside Baltimore.

The device industry's DTC spending remains small by comparison to that for pharmaceuticals – according to TNS Media Intelligence, device makers spent $193 million on advertising last year – but it's growing fast. In convening the hearings, Kohl said the device industry was “beginning to get into the game,” and that it was time the FDA began subjecting it to the same scrutiny as it does pharmaceutical manufacturers.
Share this article:

Email Newsletters

More in News

Sanofi expands Gaucher disease portfolio

Sanofi expands Gaucher disease portfolio

The oral medication Cerdelga joins Cerezyme in its Fabry disease arsenal. Sanofi expects the drug will be priced "on par" with Cerezyme, which goes for around $300,000 a year in ...

Amicus seeks to upset Fabry market

Amicus seeks to upset Fabry market

Phase-III tests indicate patients may be able to switch from injectable enzyme-replacement therapies, like Fabrazyme, to the firm's oral drug.

Five things for pharma marketers to know: Wednesday, August 20

Five things for pharma marketers to know: Wednesday, ...

Novartis explores the virtual care space, a court has dismissed a lawsuit against IPAB, Doctors Without Borders calls the Ebola outbreak "a complete disaster" and Pfizer becomes the first pharma ...